[go: up one dir, main page]

EP4271374A4 - Sos1-inhibitoren und verwendungen davon - Google Patents

Sos1-inhibitoren und verwendungen davon

Info

Publication number
EP4271374A4
EP4271374A4 EP21916206.2A EP21916206A EP4271374A4 EP 4271374 A4 EP4271374 A4 EP 4271374A4 EP 21916206 A EP21916206 A EP 21916206A EP 4271374 A4 EP4271374 A4 EP 4271374A4
Authority
EP
European Patent Office
Prior art keywords
sos1 inhibitors
sos1
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21916206.2A
Other languages
English (en)
French (fr)
Other versions
EP4271374A1 (de
Inventor
Andreas Buckl
Severin Thompson
Adrian L Gill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revolution Medicines Inc
Original Assignee
Revolution Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revolution Medicines Inc filed Critical Revolution Medicines Inc
Publication of EP4271374A1 publication Critical patent/EP4271374A1/de
Publication of EP4271374A4 publication Critical patent/EP4271374A4/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP21916206.2A 2020-12-29 2021-12-16 Sos1-inhibitoren und verwendungen davon Pending EP4271374A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063131674P 2020-12-29 2020-12-29
PCT/US2021/063685 WO2022146698A1 (en) 2020-12-29 2021-12-16 Sos1 inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
EP4271374A1 EP4271374A1 (de) 2023-11-08
EP4271374A4 true EP4271374A4 (de) 2025-03-05

Family

ID=82260817

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21916206.2A Pending EP4271374A4 (de) 2020-12-29 2021-12-16 Sos1-inhibitoren und verwendungen davon

Country Status (4)

Country Link
EP (1) EP4271374A4 (de)
JP (1) JP2024503280A (de)
CN (1) CN116916914A (de)
WO (1) WO2022146698A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN116041344A (zh) * 2021-10-28 2023-05-02 北京望实智慧科技有限公司 双环杂芳基甲酰胺化合物作为sos1抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
TW202446388A (zh) 2023-04-14 2024-12-01 美商銳新醫藥公司 Ras抑制劑之結晶形式、含有其之組合物及其使用方法
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275570A1 (en) * 2005-04-06 2009-11-05 Astrazeneca Ab Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
JP5908493B2 (ja) * 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インドール
KR20210146287A (ko) * 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도

Also Published As

Publication number Publication date
WO2022146698A1 (en) 2022-07-07
EP4271374A1 (de) 2023-11-08
JP2024503280A (ja) 2024-01-25
CN116916914A (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
EP4271374A4 (de) Sos1-inhibitoren und verwendungen davon
EP4326720A4 (de) Parp1-inhibitoren und verwendungen davon
EP4110333A4 (de) Sos1-inhibitoren
EP3768664A4 (de) Shp2-inhibitoren und verwendungen davon
EP4188383A4 (de) Sos1-inhibitoren
EP4216951A4 (de) Kras-g12d-hemmer
EP3746075A4 (de) Gcn2-inhibitoren und verwendungen davon
EP3572400C0 (de) Ezh2-inhibitor und verwendung davon
EP3866789A4 (de) Tyk2-inhibitoren und verwendungen davon
EP3689876A4 (de) Pde9-inhibitor und verwendung davon
EP3914357A4 (de) Tyk2-inhibitoren und verwendungen davon
EP4358963A4 (de) Sos1-inhibitoren
EP3741758A4 (de) Bromdomäneninhibitorverbindung und verwendung davon
EP3820469A4 (de) Ep4-inhibitoren und verwendung davon
EP4192836A4 (de) Atr-inhibitoren und verwendungen davon
DK3621694T5 (da) Lrrc33-inhibitorer og anvendelse heraf
EP4001276A4 (de) Aurora-kinase-inhibitor und verwendung davon
EP4185381A4 (de) Thiophen-hsd17b13-inhibitoren und verwendungen davon
EP3744722A4 (de) Ss-lactamase-hemmer und verwendung davon
DK4196479T3 (da) Substituerede pyridotriazinforbindelser og anvendelser deraf
EP4389738A4 (de) Sos1-inhibitor und verwendung davon
EP4161917A4 (de) Grk2-inhibitoren und verwendungen davon
EP4210694A4 (de) Plasmakallikreinhemmer
EP4244205A4 (de) Ire1alpha-inhibitoren und verwendungen davon
EP3976009A4 (de) Bax-inhibitoren und verwendungen davon

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250203

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/04 20060101ALI20250128BHEP

Ipc: C07D 409/04 20060101ALI20250128BHEP

Ipc: C07D 405/12 20060101ALI20250128BHEP

Ipc: C07D 405/04 20060101ALI20250128BHEP

Ipc: C07D 403/04 20060101ALI20250128BHEP

Ipc: C07D 307/20 20060101ALI20250128BHEP

Ipc: C07D 231/56 20060101ALI20250128BHEP

Ipc: A61P 35/00 20060101ALI20250128BHEP

Ipc: C07D 401/04 20060101ALI20250128BHEP

Ipc: A61K 31/404 20060101AFI20250128BHEP